课题基金 / 基金详情

PSMA/CAIX-targeting radioligands to improve the management of clear cell renal cell carcinoma

PSMA/CAIX-targeting radioligands to improve the management of clear cell renal cell carcinoma
PSMA/CAIX 靶向放射性配体改善透明细胞肾细胞癌的治疗
批准号:
450504
负责人:
Lin Kuo-Shyan
金额:
$53.22万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2021
资助国家:
加拿大
项目状态:
未结题
起止时间:
2021-09-01 至 2026-09-01

项目摘要

项目成果

Lin Kuo-Shyan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Kidney cancer is one of the most lethal cancers in Canada with low five-year survival rate. The most common kidney cancer is clear cell renal cell carcinoma (ccRCC). Treatment options for ccRCC are limited, and effective diagnostic and therapeutic agents
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Next-generation GRPR-targeting radiopharmaceuticals with improved in vivo stability and minimized pancreas uptake
  • 批准号:
    460171
  • 项目类别:
    Operating Grants
  • 资助金额:
    $38.12万
  • 财政年份:
    2022
  • 负责人:
    Lin Kuo-Shyan
  • 依托单位:
Simultaneously targeting cancer cells and tumor stroma to improve detection sensitivity and therapeutic efficacy of radiopharmaceuticals
  • 批准号:
    450505
  • 项目类别:
    Operating Grants
  • 资助金额:
    $56.29万
  • 财政年份:
    2021
  • 负责人:
    Lin Kuo-Shyan
  • 依托单位:
Cleavable linkers to reduce kidney uptake of peptide radiopharmaceuticals
  • 批准号:
    388054
  • 项目类别:
    Operating Grants
  • 资助金额:
    $56.29万
  • 财政年份:
    2018
  • 负责人:
    Lin Kuo-Shyan
  • 依托单位:
PET tracers for imaging bradykinin B1 receptor expression in cancer
  • 批准号:
    265502
  • 项目类别:
    Operating Grants
  • 资助金额:
    $28.58万
  • 财政年份:
    2012
  • 负责人:
    Lin Kuo-Shyan
  • 依托单位:
海外基金